drugset
drugset / Trial / NCT05171075

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075 ↗

Phase 3 Terminated 417 enrolled Anthos Therapeutics, Inc. Novartis Pharmaceuticals · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Timeline

Start
2022-09-27
Primary completion
2026-04-10
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Abelacimab Monoclonal antibody 150 mg Intravenous
Comparator Dalteparin sodium Other / unclassified 150 iu/kg Subcutaneous

Indications

pulmonary embolism venous thromboembolism